Insights
Search Results
Client Highlights
10.30.26
Wilson Sonsini Advises Bambusa Therapeutics on $168.9 Million Initial Public Offering
On October 29, 2026, Bambusa Therapeutics, a Boston-based clinical-stage company developing next-generation, long-acting precision bispecific antibodies for immunology and inflammation, announced the pricing of its upsized initial public offering of 10,555,555 shares of its common stock at a public offering price of $16.00 per share. Bambusa’s common stock began trading on the Nasdaq Global Select Market today under the ticker symbol “BBTX.” Wilson Sonsini Goodrich & Rosati advised Bambusa on the transaction.
Alerts
10.28.26
New COINS of the Realm: Treasury’s Implementation of COINS Act Reaches Biotech, AI, and More
On Thursday, October 22, 2026, the U.S. Department of the Treasury (Treasury) issued a notice of proposed rulemaking (the Proposed Rule) to replace and expand the current Outbound Investment Security Program (the OISP). The Proposed Rule would implement Subtitle C of the Comprehensive Outbound Investment National Security Act of 2025 (the COINS Act) enacted last December, which we previously discussed here. The Proposed Rule would establish new regulations (to be codified at 31 C.F.R. Part 851) that prohibit U.S. persons from making certain investments, and require them to notify Treasury of others, when the target is a company or other person tied to the People’s Republic of China (PRC, including Hong Kong and Macau), Cuba, Iran, North Korea, Russia, or (in specified circumstances) Venezuela (each such company or other person being a “covered foreign person”) that is engaged in specified technologies. Comments on the Proposed Rule are due December 7, 2026.
Client Highlights
10.28.26
Wilson Sonsini Advises Orbus Therapeutics on IP Matters Related to Acquisition by US WorldMeds
On October 27, 2026, US WorldMeds, a specialty pharmaceutical company, and Orbus Therapeutics, a privately held pharmaceutical company developing investigational eflornithine for rare and serious brain tumors, announced a definitive merger agreement under which US WorldMeds has acquired Orbus. Wilson Sonsini Goodrich & Rosati advised Orbus on IP matters in connection with the transaction.
Client Highlights
10.23.26
Firm Advises PepStar Therapeutics on Patent Matters Related to Acquisition of Inflammation Drug Program by Gilead Sciences
On October 22, 2026, Gilead Sciences, a biopharmaceutical company pursuing breakthroughs in medicine, announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company, for $1.275 billion in upfront cash consideration, subject to customary adjustments. The transaction is expected to close later in 2026. Wilson Sonsini Goodrich & Rosati is advising PepStar on patent matters related to the transaction.
Client Highlights
10.23.26
Wilson Sonsini Advises Prana Therapies on IP Matters Related to Acquisition by Bolt Biotherapeutics
On October 23, 2026, Bolt Biotherapeutics, a clinical-stage biotechnology company, announced the acquisition of Prana Therapies, a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, Bolt Biotherapeutics will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned. Wilson Sonsini Goodrich & Rosati advised Prana Therapies on the intellectual property matters related to the transaction.
Client Highlights
10.19.26
Firm Advises Alector on $75 Million Underwritten Offering
On October 16, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock at an offering price of $2.05 per share, which represents a premium of approximately 7.3 percent over the closing price on October 15, 2026. The gross proceeds to Alector from this offering are expected to be $75,030,000 before deducting the underwriting discounts and commissions and other estimated offering expenses. The financing includes participation from new and existing investors, including TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital, among others. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.
Client Highlights
10.16.26
Wilson Sonsini Advises Iambic Therapeutics on $150 Million Initial Public Offering
Wilson Sonsini advised Iambic Therapeutics, a clinical-stage life sciences and technology company advancing novel medicines using its AI-driven platform, in connection with the company’s $150 million initial public offering (IPO). Iambic issued 9,375,000 shares of its common stock at a public offering price of $16 per share, with a 30-day option for the underwriters to purchase up to an additional 1,406,250 shares. Iambic’s common stock began trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol “IAM.”
Client Highlights
10.14.26
Wilson Sonsini Advises Prolific Machines on Patent and Trademark Matters Related to $50 Million Series B2 Financing
On October 14, 2026, Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions, announced the initial closing of its $50 million Series B2 financing led by Atoms & Bits and Nant Capital. Wilson Sonsini Goodrich & Rosati advised Prolific Machines on patent and trademark matters related to the transaction.
Client Highlights
10.12.26
Firm Advises Oxford Science Enterprises on IP Matters Related to Sensible’s $47 Million Financing
On October 6, 2026, Sensible Biotechnologies (Sensible), a biotechnology company developing a first-of-its-kind platform for naturally modified mRNA medicines, announced that it has secured $47 million in financing to advance and scale its integrated mRNA technology. The financing includes a Series A led by Oxford Science Enterprises (OSE) and up to $20 million in non-dilutive funding from the Government of Slovakia and the European Union. Wilson Sonsini Goodrich & Rosati advised OSE on IP due diligence related to the transaction.
Client Highlights
10.08.26
Wilson Sonsini Advises Atrium Therapeutics on Patent Matters Related to $50 Million Private Placement
On October 8, 2026, Atrium Therapeutics, a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, announced that it has entered into a securities purchase agreement with a group of leading institutional investors for a private placement financing. The financing is expected to result in aggregate gross proceeds of approximately $50 million, before deducting placement agent fees and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Atrium Therapeutics on patent matters related to the transaction.
Client Highlights
10.06.26
Firm Advises Alector on Exclusive Global License Agreement with Genentech
On October 5, 2026, Alector, a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, announced it has entered into an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize Alector’s AL050 program, its brain-penetrant engineered glucocerebrosidase (GCase) ERT. Under the terms of the agreement, Alector will receive an upfront payment of $100 million and is also eligible to receive tiered royalties on net sales and additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones. Wilson Sonsini Goodrich & Rosati advised Alector on the transaction.
Client Highlights
10.01.26
Wilson Sonsini Advises SpyGlass Pharma on Acquisition of Advanced Vision Science
On October 1, 2026, SpyGlass Pharma, a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions, announced the acquisition of all outstanding shares of Advanced Vision Science (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million dollars in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma for its Phase 3 lead product candidate (the BIM-IOL System) and accelerates pathway to adding premium lens options into its IOL-based drug delivery system. Wilson Sonsini Goodrich & Rosati advised SpyGlass Pharma on the transaction.